Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Glioma 2Glioblastoma 2Cholangiocarcinoma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

venetoclax 1olutasidenib 1magrolimab 1fludarabine 1cc-486 1Mitoxantrone 1Etoposide 1Dexamethasone 1Decitabine 1Cytarabine 1Cyclophosphamide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myeloid Malignancies × olutasidenib × Clear all
NCT06668584 2026-03-04

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

M.D. Anderson Cancer Center

Phase 2 Recruiting
31 enrolled

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡